ArticleThe European respiratory journal2025
Nasal CPAP increases alveolar number in a rhesus monkey model of moderate prematurity.
Article in The European respiratory journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Extended Continuous Positive Airway Pressure in Preterm Infants Increases Lung Growth at 6 Months: A Randomized Controlled Trial.American journal of respiratory and critical care medicine · 2025Trial
- Extending CPAP in stable preterm infants to increase lung growth and development as measured by pulmonary function testing.Seminars in perinatology · 2025Review
Corrections and comments
- Commented on by
Authors and funding
12 authors.
Funding
Abstract
backgroundMost premature human infants are born in the moderate to late preterm (MLP) range, ≥30 to <37 weeks gestation, and demonstrate increased incidence of wheeze and respiratory illness as they age. Animal models suggest that mechanical lung distention stimulates lung growth and alveolar development. To determine if nasal continuous positive airway pressure (nCPAP) influences MLP infant lung development, we developed a rhesus monkey model of moderate prematurity, randomised to 9 days of nCPAP or sham nCPAP.
methodsTimed-pregnant fetuses were delivered by elective hysterotomy at gestational age (GA) 140±1 days (85% gestation; term=165 days; human equivalent of 32-34 weeks) or at GA-149±1 days as a relative gestational age reference (GA-control). The day after delivery, the GA-140 animals were treated with nCPAP or sham nCPAP for 9 days, 12 consecutive hours each day. Pulmonary function testing followed by necropsy for analysis of lung structure and gene expression was performed on the equivalent of GA-150 for all animals.
resultsThe nCPAP and sham groups were clinically similar but distinct from the GA-control group. Stereological analysis of lung structure showed significantly increased numbers of alveoli in the nCPAP group compared to the sham group. Other functional and anatomical changes were consistent with increased alveolarisation. Gene expression between the nCPAP and sham groups remained highly similar and distinct from GA-control animals.
conclusionsWe show that nCPAP in MLP infants stimulates alveolarisation with relatively few other changes. How this may benefit subsequent infant respiratory health requires further study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.